Puma Biotechnology Inc (NASDAQ: PBYI) stock closed at $5.35 on 3/21/24 after a major increase of 14.0%. Moreover, unusually high trading volume at 175% of normal accompanied the advance. The stock is unchanged during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
PBYI’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Puma Biotechnology has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Puma Biotechnology has a neutral Appreciation Score of 41 but a very high Power Rating of 86, producing the Positive Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment